Citius Oncology Net Income

The latest net income for CTOR is $-43M as of March 2026. That compares with $-14M in the prior-year period — down 195.3% year over year. That is below the sector sector average of $110M. Investors often review this figure alongside Citius Oncology's historical trend and sector peers before judging valuation or financial health.

Over the past year, CTOR's net income moved from $-14M to $-43M — a 195.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Citius Oncology's operating scale or balance-sheet position.

Against its sector companies, CTOR currently prints $-43M for net income, while the sector average sits near $110M. That is roughly 139.9% below the sector mean. Large gaps often invite a closer look at Citius Oncology's growth, margins, and balance sheet.

A net income figure of $-43M for CTOR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $110M. Explore the charts below for those layers of context.

After noting CTOR's net income ($-43M), review year-over-year change from $-14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.